Local (but not systemic) photobiomodulation treatment reduces mast cell degranulation, eicosanoids, and Th2 cytokines in an experimental model of allergic rhinitis

Allergic rhinitis (AR) is an inflammatory disorder of the nasal mucosa, and is a worldwide health problem with a significant impact on the quality of life. The main goal of AR treatment is to relieve symptoms. However, standard treatments have considerable side effects or are not effective. Photobio...

Full description

Saved in:
Bibliographic Details
Published in:Lasers in medical science 2022-04, Vol.37 (3), p.1953-1962
Main Authors: Schapochnik, Adriana, Klein, Simone, Brochetti, Robson, Alonso, Paula Tatiane, Damazo, Amílcar Sabino, de Souza Setubal Destro, Maria Fernanda, Hamblin, Michael R., Lino-dos-Santos-Franco, Adriana
Format: Article
Language:English
Subjects:
Allergic rhinitis
Animal models
Animals
Cytokines
Degranulation
Dentistry
Eicosanoids
Gene expression
Inflammatory diseases
Interleukin 10
Interleukin 4
Lasers
Leukotriene B4
Light emitting diodes
Light therapy
Lymphocytes T
Mathematical models
Medicine
Medicine & Public Health
Mucosa
Nasopharynx
Nose
Optical Devices
Optics
Original Article
Ovalbumin
Parameters
Photonics
Quality of life
Quantum Optics
Rhinitis
Side effects
Thromboxane A2
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Allergic rhinitis (AR) is an inflammatory disorder of the nasal mucosa, and is a worldwide health problem with a significant impact on the quality of life. The main goal of AR treatment is to relieve symptoms. However, standard treatments have considerable side effects or are not effective. Photobiomodulation (PBM) therapy has emerged as an alternative treatment. Here, we evaluated the effects of transcutaneous systemic (tail) or local (skin over nostrils) PBM using a 660-nm light-emitting diode (LED) array. Adult rats were assigned into 4 groups: basal, as non-manipulated animals; Sham, as rats sensitized with 7 intradermal injections of ovalbumin (OVA) plus alum followed by intranasal instillation with OVA (2%) daily for 7 days; and the LPBM and SPBM groups, in which the animals were treated with PBM (local or systemic) immediately after the last instillation of OVA (1%) daily for 3 days. Our results showed that local PBM treatment reduced mast cell degranulation in the nasopharynx and nostrils; levels of leukotriene B4, thromboxane A2, and interleukin 4 (IL-4) in the nasopharynx; and gene expression of IL-4. Moreover, we showed higher levels and gene expression of IL-10 after local PBM treatment. Systemic PBM treatment did not change any of the evaluated parameters. In conclusion, our data showed that local (but not systemic) treatment with PBM could improve parameters related to AR in an animal model, and should be tested clinically.
ISSN:1435-604X
0268-8921
1435-604X
DOI:10.1007/s10103-021-03456-1